In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Quest Diagnostics, Ciphergen develop new assays

Executive Summary

Ciphergen and Quest Diagnostics will jointly develop and commercialize up to three assays from Ciphergen's pipeline over the next three years. Quest gets nonexclusive worldwide rights to sell resulting tests and an exclusive license for up to five years following launch for territories in which Quest has a significant presence. The partners will use Ciphergen's proprietary SELDI ProteinChip technology, a platform that provides researchers with tools to use in protein discovery, characterization, and identification, and predictive assay development.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies